15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Rhythm Pharmaceuticals Inc, 14 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $105.00 to $160.00, a moderate spread. The average target of $142.31 sits 41% above the current $101.05. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.74 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Strong Buy
Strong Buy00%
Buy1493%
Hold17%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Rhythm Pharmaceuticals Inc.
As of Sep, 13 of 14 firms rate RYTM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RYTM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.74
Range $-0.93 – $-0.58 · 12 analysts · +1% YoY
Next period, 12 analysts expect Rhythm Pharmaceuticals Inc to earn $-0.74 a share (range $-0.93 – $-0.58), versus $-0.73 a year earlier. Full-year consensus is $-3.07, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$98.0M
Range $89.5M – $112.0M · 12 analysts · +71% YoY
Revenue is expected to reach $98.0M (range $89.5M – $112.0M), +71.2% year-over-year. Full-year consensus is $313.7M, rising to $560.2M next year.
Top analysts covering Rhythm Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RYTM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$136.00+34.6% to target
Overall win rate
64%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$152.00+50.4% to target
Overall win rate
47%
+ Follow
#3
Joseph Stringer
Needham · Rank #195
Buy
$130.00+28.6% to target
Overall win rate
36%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #307
Hold
No targeton RYTM
Overall win rate
37%
+ Follow
#5
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$105.00+3.9% to target
Overall win rate
36%
+ Follow
RYTM stock forecast FAQ
What is RYTM's average 12-month price target?+
The 13 analysts with a live target average $142.31 for Rhythm Pharmaceuticals Inc over the next 12 months, ranging from a $160.00 high to a $105.00 low.
Is RYTM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 15 analyst ratings, 14 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RYTM?+
The Street-high target is $160.00 (Citizens), and the Street-low is $105.00 (HC Wainwright & Co.). The average of all 13 active targets is $142.31.
How many Wall Street analysts cover RYTM?+
15 analysts have an active rating on Rhythm Pharmaceuticals Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering RYTM?+
Among analysts who currently cover RYTM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Buy with a $136.00 target.
What is Rhythm Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.74 per share (range $-0.93 – $-0.58) across 12 analysts. Full-year EPS is projected at $-3.07, rising to $-0.61 the following year.
How much revenue is Rhythm Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $98.0M (range $89.5M – $112.0M). Full-year revenue is projected at $313.7M, growing to $560.2M next year.
Have analysts been upgrading or downgrading RYTM lately?+
As of Sep, 13 of 14 firms rate RYTM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RYTM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
